Wolfe Medical Group, a specialist medical technology company that operates under the brand “Gen-X”, is gearing up for its debut on the ASX after joining forces with The Public Listing Co. to facilitate a listing via IPO. The company provides a range of market leading treatments in regenerative medicine and men’s health.
The Public Listing Co’s Managing Director, James Mawhinney, commented on the engagement –
“We are excited about the opportunity to assist Wolfe Medical Group with their growth plans. Stem cell therapy and regenerative medicine is a high growth industry and one that is receiving a substantial amount of investor attention.”
Wolfe Medical Group plans on undertaking an IPO in 2016 after some corporate restructuring work and interim capital raising that will see the company increase its national footprint and access to further intellectual property and patents in regenerative medicine.